Pharmacologic infusion of activated protein C (APC) improves survival in severe sepsis, and platelet factor 4 (PF4) accelerates APC generation in a primate thrombin-infusion model. We now tested whether endogenous platelet PF4 content affects APC generation. Mice completely deficient in PF4 (mPF4 ؊/؊ ) had impaired APC generation and survival after thrombin infusion, similar to the impairment seen in heterozygote protein C-deficient (PC ؉/؊ ) mice. Transgenic mice overexpressing human PF4 (hPF4 ؉ ) had increased plasma APC generation. Overexpression of platelet PF4 compensated for the defect seen in PC ؉/؊ mice. In both a thrombin and a lipopolysaccharide (LPS) survival model, hPF4 ؉ and PC ؉/؊ /hPF4 ؉ mice had improved survival. Further, infusion of hPF4 ؉ platelets improved survival of wild-type mice after an LPS challenge.
IntroductionIn addition to its anticoagulant function, activated protein C (APC) has been shown to exert an antiinflammatory influence 1,2 and inhibit apoptosis. [3][4][5] All of these effects may contribute to the efficacy of APC infusions in improving outcome in various animal models of inflammation 6-9 and in reducing mortality in patients with sepsis. [10][11][12] In a lipopolysaccharide (LPS)-induced survival model of sepsis, heterozygous protein C-deficient (PC ϩ/Ϫ ) mice have enhanced vulnerability to death, 6,8 reinforcing the crucial role played by endogenously generated APC in this setting. Recent clinical studies demonstrate that basal PC levels are an independent predictor of sepsis outcome 13 and that endogenous vascular generation of APC is a crucial determinant of survival in sepsis. 14 We have shown previously that platelet factor 4 (PF4, CXCL4) can enhance APC generation in vitro 15 and in vivo 16 ; however, the biologic impact of endogenous, platelet-derived PF4 in regulating systemic APC generation has not been tested. In this study, we examined whether endogenously released PF4 from activated platelets stimulates APC generation in response to thrombin infusion and improves outcome in thrombosis/inflammatory models. These studies were done in mice with targeted disruption of the murine Pf4 gene (mPf4 Ϫ/Ϫ ) and transgenic mice that overexpressed human PF4 (hPF4 ϩ ). 17 We found that platelet PF4 content correlated with APC generation after thrombin infusion and survival after thrombin or LPS challenge and that released PF4 can compensate for the lower PC levels in PC ϩ/Ϫ mice. 6,8 Further, infusion of platelets with high PF4 content is protective in the LPS challenge model, supporting endogenous PF4 as an important variable in outcome from sepsis and suggesting a novel therapy for sepsis.
Materials and methodsThe mPf4 Ϫ/Ϫ and hPF4 ϩ mice have been previously described. 17,18 PC ϩ/Ϫ mice were supplied by Dr Frank Castellino. 19 All mice were on a common C57Bl6 background, and littermate wild-type (WT) controls were used. Murine studies were approved by the Children's Hospital of Philadelphia institutional animal care and use committee.Circulating plasma APC levels were mea...